Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-06-17

AUTHORS

Bipin Sethi, Khalid Al-Rubeaan, Mustafa Unubol, Maria A. Mabunay, Baptiste Berthou, Valerie Pilorget, Shireene R. Vethakkan, Gustavo Frechtel

ABSTRACT

IntroductionThe efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa.MethodsThe ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin [HbA1c] 7.5–10%) on BI were switched to Gla-300. The primary endpoint was change in HbA1c from baseline to 26 weeks. Key secondary endpoints were changes in HbA1c (week 12), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week 26. The safety and tolerability of Gla-300 were also assessed.ResultsA total of 372 (50% male) participants were included, with mean (standard deviation [SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA1c 8.67 (0.77)% (71.22 [8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100 U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA1c (− 0.82%; primary endpoint), FPG and SMPG levels at week 26. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48 U (0.35 U/kg) at baseline to 39.01 U (0.50 U/kg) at week 26. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event.ConclusionIn people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions.ClinicalTrials.gov identifierNCT03760991. More... »

PAGES

1395-1408

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01271-7

DOI

http://dx.doi.org/10.1007/s13300-022-01271-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1148759894

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35713873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Care Hospital, 500034, Hyderabad, India", 
          "id": "http://www.grid.ac/institutes/grid.413417.4", 
          "name": [
            "Care Hospital, 500034, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sethi", 
        "givenName": "Bipin", 
        "id": "sg:person.01330445170.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330445170.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City, Riyadh, Saudi Arabia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City, Riyadh, Saudi Arabia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Al-Rubeaan", 
        "givenName": "Khalid", 
        "id": "sg:person.01240114634.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240114634.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.34517.34", 
          "name": [
            "Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unubol", 
        "givenName": "Mustafa", 
        "id": "sg:person.0744460617.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744460617.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Singapore", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Sanofi, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mabunay", 
        "givenName": "Maria A.", 
        "id": "sg:person.014000313025.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014000313025.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IT&M Stats for Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "IT&M Stats for Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berthou", 
        "givenName": "Baptiste", 
        "id": "sg:person.013462052247.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013462052247.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilorget", 
        "givenName": "Valerie", 
        "id": "sg:person.0625112120.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Malaya Medical Centre, Kuala Lumpur, Malaysia", 
          "id": "http://www.grid.ac/institutes/grid.413018.f", 
          "name": [
            "University Malaya Medical Centre, Kuala Lumpur, Malaysia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vethakkan", 
        "givenName": "Shireene R.", 
        "id": "sg:person.01247721370.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247721370.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital de Cl\u00ednicas, Universidad de Buenos Aires, Buenos Aires, Argentina", 
          "id": "http://www.grid.ac/institutes/grid.412714.5", 
          "name": [
            "Hospital de Cl\u00ednicas, Universidad de Buenos Aires, Buenos Aires, Argentina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frechtel", 
        "givenName": "Gustavo", 
        "id": "sg:person.01026744106.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026744106.67"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-019-0568-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112140157", 
          "https://doi.org/10.1007/s13300-019-0568-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00734-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122984738", 
          "https://doi.org/10.1007/s13300-019-00734-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-019-05078-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123816239", 
          "https://doi.org/10.1007/s00125-019-05078-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-020-01436-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1129442758", 
          "https://doi.org/10.1007/s12325-020-01436-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-022-01266-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1147731740", 
          "https://doi.org/10.1007/s13300-022-01266-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01074-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1139077339", 
          "https://doi.org/10.1007/s13300-021-01074-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-020-00902-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130191599", 
          "https://doi.org/10.1007/s13300-020-00902-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-17", 
    "datePublishedReg": "2022-06-17", 
    "description": "IntroductionThe efficacy and safety of switching to insulin glargine 300\u00a0U/mL (Gla-300) in type\u00a02 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa.MethodsThe ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase\u00a0IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin [HbA1c] 7.5\u201310%) on BI were switched to Gla-300. The primary endpoint was change in HbA1c from baseline to 26\u00a0weeks. Key secondary endpoints were changes in HbA1c (week\u00a012), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week\u00a026. The safety and tolerability of Gla-300 were also assessed.ResultsA total of 372 (50% male) participants were included, with mean (standard deviation [SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA1c 8.67 (0.77)% (71.22 [8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100\u00a0U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA1c (\u2212\u20090.82%; primary endpoint), FPG and SMPG levels at week\u00a026. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48\u00a0U (0.35\u00a0U/kg) at baseline to 39.01\u00a0U (0.50\u00a0U/kg) at week\u00a026. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event.ConclusionIn people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions.ClinicalTrials.gov identifierNCT03760991.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01271-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "self-monitored plasma glucose", 
      "basal insulin", 
      "Gla-300", 
      "previous basal insulin", 
      "hypoglycaemia events", 
      "plasma glucose", 
      "insulin glargine 300 U/mL", 
      "glargine 300 U/mL", 
      "neutral protamine Hagedorn (NPH) insulin", 
      "severe hypoglycaemia events", 
      "key secondary endpoint", 
      "insulin glargine 100", 
      "IntroductionThe efficacy", 
      "glargine 300", 
      "primary endpoint", 
      "secondary endpoints", 
      "glargine 100", 
      "mean HbA1c", 
      "glycaemic control", 
      "diabetes mellitus", 
      "ResultsA total", 
      "optimal titration", 
      "titration algorithm", 
      "lower incidence", 
      "type 2", 
      "HbA1c", 
      "T2DM", 
      "BI dose", 
      "weeks", 
      "insulin", 
      "baseline", 
      "different ethnicities", 
      "efficacy", 
      "significant reduction", 
      "dose", 
      "endpoint", 
      "safety", 
      "participants", 
      "Western European populations", 
      "total", 
      "European populations", 
      "glucose", 
      "mellitus", 
      "tolerability", 
      "hypoglycaemia", 
      "mL", 
      "geographic regions", 
      "multiple geographic regions", 
      "Interventional", 
      "FPG", 
      "years", 
      "incidence", 
      "study", 
      "adults", 
      "geographical regions", 
      "people", 
      "duration", 
      "ethnicity", 
      "events", 
      "changes", 
      "population", 
      "levels", 
      "control", 
      "Latin America", 
      "reduction", 
      "data", 
      "region", 
      "types", 
      "East Africa", 
      "Africa", 
      "titration", 
      "Asia", 
      "America", 
      "phase", 
      "algorithm"
    ], 
    "name": "Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study", 
    "pagination": "1395-1408", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1148759894"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01271-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35713873"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01271-7", 
      "https://app.dimensions.ai/details/publication/pub.1148759894"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_947.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01271-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01271-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01271-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01271-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01271-7'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      107 URIs      92 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01271-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Naedcd603fd73442e9348bfa94f0b5041
4 schema:citation sg:pub.10.1007/s00125-019-05078-3
5 sg:pub.10.1007/s12325-020-01436-5
6 sg:pub.10.1007/s13300-019-00734-8
7 sg:pub.10.1007/s13300-019-0568-8
8 sg:pub.10.1007/s13300-020-00902-1
9 sg:pub.10.1007/s13300-021-01074-2
10 sg:pub.10.1007/s13300-022-01266-4
11 schema:datePublished 2022-06-17
12 schema:datePublishedReg 2022-06-17
13 schema:description IntroductionThe efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa.MethodsThe ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin [HbA1c] 7.5–10%) on BI were switched to Gla-300. The primary endpoint was change in HbA1c from baseline to 26 weeks. Key secondary endpoints were changes in HbA1c (week 12), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week 26. The safety and tolerability of Gla-300 were also assessed.ResultsA total of 372 (50% male) participants were included, with mean (standard deviation [SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA1c 8.67 (0.77)% (71.22 [8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100 U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA1c (− 0.82%; primary endpoint), FPG and SMPG levels at week 26. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48 U (0.35 U/kg) at baseline to 39.01 U (0.50 U/kg) at week 26. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event.ConclusionIn people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions.ClinicalTrials.gov identifierNCT03760991.
14 schema:genre article
15 schema:isAccessibleForFree true
16 schema:isPartOf N6ee35b4da1f0489696f379d65d48aeb2
17 Ndd5f20921ba84cd89fcbc08ea110513d
18 sg:journal.1044057
19 schema:keywords Africa
20 America
21 Asia
22 BI dose
23 East Africa
24 European populations
25 FPG
26 Gla-300
27 HbA1c
28 Interventional
29 IntroductionThe efficacy
30 Latin America
31 ResultsA total
32 T2DM
33 Western European populations
34 adults
35 algorithm
36 basal insulin
37 baseline
38 changes
39 control
40 data
41 diabetes mellitus
42 different ethnicities
43 dose
44 duration
45 efficacy
46 endpoint
47 ethnicity
48 events
49 geographic regions
50 geographical regions
51 glargine 100
52 glargine 300
53 glargine 300 U/mL
54 glucose
55 glycaemic control
56 hypoglycaemia
57 hypoglycaemia events
58 incidence
59 insulin
60 insulin glargine 100
61 insulin glargine 300 U/mL
62 key secondary endpoint
63 levels
64 lower incidence
65 mL
66 mean HbA1c
67 mellitus
68 multiple geographic regions
69 neutral protamine Hagedorn (NPH) insulin
70 optimal titration
71 participants
72 people
73 phase
74 plasma glucose
75 population
76 previous basal insulin
77 primary endpoint
78 reduction
79 region
80 safety
81 secondary endpoints
82 self-monitored plasma glucose
83 severe hypoglycaemia events
84 significant reduction
85 study
86 titration
87 titration algorithm
88 tolerability
89 total
90 type 2
91 types
92 weeks
93 years
94 schema:name Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study
95 schema:pagination 1395-1408
96 schema:productId N50a562fa4f704b89a7363bce07f167df
97 N8ea1fbec8353431eb6a2b138c02a79c3
98 Nddf2f6ecc6404bd3a25ac018d7c6e1a8
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1148759894
100 https://doi.org/10.1007/s13300-022-01271-7
101 schema:sdDatePublished 2022-12-01T06:44
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Ne951048e8e3040899150ca7e92c12a25
104 schema:url https://doi.org/10.1007/s13300-022-01271-7
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N4012abb49bfe4828a195e2717d480617 rdf:first sg:person.013462052247.14
109 rdf:rest N7ec7c908a3254a018da352f2189590b9
110 N4f431a7fd89749cabcce63d8910013aa rdf:first sg:person.01247721370.87
111 rdf:rest Nc28fc994514042a7a4c1d3b9a50bec85
112 N50a562fa4f704b89a7363bce07f167df schema:name dimensions_id
113 schema:value pub.1148759894
114 rdf:type schema:PropertyValue
115 N63fd6d65ab9d45caaf46cfed850b8381 rdf:first sg:person.014000313025.34
116 rdf:rest N4012abb49bfe4828a195e2717d480617
117 N6ee35b4da1f0489696f379d65d48aeb2 schema:volumeNumber 13
118 rdf:type schema:PublicationVolume
119 N7ec7c908a3254a018da352f2189590b9 rdf:first sg:person.0625112120.31
120 rdf:rest N4f431a7fd89749cabcce63d8910013aa
121 N89ab70672eff46a7b95dfa8d03fe70c8 rdf:first sg:person.01240114634.78
122 rdf:rest N9b5aeba4d7154f0994d9244f6faf9beb
123 N8ea1fbec8353431eb6a2b138c02a79c3 schema:name doi
124 schema:value 10.1007/s13300-022-01271-7
125 rdf:type schema:PropertyValue
126 N9b5aeba4d7154f0994d9244f6faf9beb rdf:first sg:person.0744460617.11
127 rdf:rest N63fd6d65ab9d45caaf46cfed850b8381
128 Naedcd603fd73442e9348bfa94f0b5041 rdf:first sg:person.01330445170.44
129 rdf:rest N89ab70672eff46a7b95dfa8d03fe70c8
130 Nc28fc994514042a7a4c1d3b9a50bec85 rdf:first sg:person.01026744106.67
131 rdf:rest rdf:nil
132 Ndd5f20921ba84cd89fcbc08ea110513d schema:issueNumber 7
133 rdf:type schema:PublicationIssue
134 Nddf2f6ecc6404bd3a25ac018d7c6e1a8 schema:name pubmed_id
135 schema:value 35713873
136 rdf:type schema:PropertyValue
137 Ne951048e8e3040899150ca7e92c12a25 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
143 schema:name Clinical Sciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1044057 schema:issn 1869-6953
146 1869-6961
147 schema:name Diabetes Therapy
148 schema:publisher Springer Nature
149 rdf:type schema:Periodical
150 sg:person.01026744106.67 schema:affiliation grid-institutes:grid.412714.5
151 schema:familyName Frechtel
152 schema:givenName Gustavo
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026744106.67
154 rdf:type schema:Person
155 sg:person.01240114634.78 schema:affiliation grid-institutes:None
156 schema:familyName Al-Rubeaan
157 schema:givenName Khalid
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240114634.78
159 rdf:type schema:Person
160 sg:person.01247721370.87 schema:affiliation grid-institutes:grid.413018.f
161 schema:familyName Vethakkan
162 schema:givenName Shireene R.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247721370.87
164 rdf:type schema:Person
165 sg:person.01330445170.44 schema:affiliation grid-institutes:grid.413417.4
166 schema:familyName Sethi
167 schema:givenName Bipin
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330445170.44
169 rdf:type schema:Person
170 sg:person.013462052247.14 schema:affiliation grid-institutes:None
171 schema:familyName Berthou
172 schema:givenName Baptiste
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013462052247.14
174 rdf:type schema:Person
175 sg:person.014000313025.34 schema:affiliation grid-institutes:None
176 schema:familyName Mabunay
177 schema:givenName Maria A.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014000313025.34
179 rdf:type schema:Person
180 sg:person.0625112120.31 schema:affiliation grid-institutes:grid.417924.d
181 schema:familyName Pilorget
182 schema:givenName Valerie
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31
184 rdf:type schema:Person
185 sg:person.0744460617.11 schema:affiliation grid-institutes:grid.34517.34
186 schema:familyName Unubol
187 schema:givenName Mustafa
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744460617.11
189 rdf:type schema:Person
190 sg:pub.10.1007/s00125-019-05078-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123816239
191 https://doi.org/10.1007/s00125-019-05078-3
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s12325-020-01436-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129442758
194 https://doi.org/10.1007/s12325-020-01436-5
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s13300-019-00734-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122984738
197 https://doi.org/10.1007/s13300-019-00734-8
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s13300-019-0568-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112140157
200 https://doi.org/10.1007/s13300-019-0568-8
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s13300-020-00902-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130191599
203 https://doi.org/10.1007/s13300-020-00902-1
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s13300-021-01074-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139077339
206 https://doi.org/10.1007/s13300-021-01074-2
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s13300-022-01266-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147731740
209 https://doi.org/10.1007/s13300-022-01266-4
210 rdf:type schema:CreativeWork
211 grid-institutes:None schema:alternateName IT&M Stats for Sanofi, Paris, France
212 Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City, Riyadh, Saudi Arabia
213 Sanofi, Singapore
214 schema:name IT&M Stats for Sanofi, Paris, France
215 Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City, Riyadh, Saudi Arabia
216 Sanofi, Singapore
217 rdf:type schema:Organization
218 grid-institutes:grid.34517.34 schema:alternateName Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkey
219 schema:name Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkey
220 rdf:type schema:Organization
221 grid-institutes:grid.412714.5 schema:alternateName Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina
222 schema:name Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina
223 rdf:type schema:Organization
224 grid-institutes:grid.413018.f schema:alternateName University Malaya Medical Centre, Kuala Lumpur, Malaysia
225 schema:name University Malaya Medical Centre, Kuala Lumpur, Malaysia
226 rdf:type schema:Organization
227 grid-institutes:grid.413417.4 schema:alternateName Care Hospital, 500034, Hyderabad, India
228 schema:name Care Hospital, 500034, Hyderabad, India
229 rdf:type schema:Organization
230 grid-institutes:grid.417924.d schema:alternateName Sanofi, Paris, France
231 schema:name Sanofi, Paris, France
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...